Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 174, Issue 24, Pages 4637-4650Publisher
WILEY
DOI: 10.1111/bph.13894
Keywords
-
Categories
Funding
- NIH [RO1-GM057603, RO1-AR060359]
- Boston Children's Hospital Intellectual and Developmental Disabilities Research Center [P30 HD-18655]
Ask authors/readers for more resources
Wnt signalling is a fundamental pathway involved in embryonic development and adult tissue homeostasis. Mutations in the pathway frequently lead to developmental defects and cancer. As such, therapeutic intervention of this pathway has generated tremendous interest. Dickkopf-1 (DKK1) is a secreted inhibitor of beta-catenin-dependent Wnt signalling and was originally characterized as a tumour suppressor based on the prevailing view that Wnt signalling promotes cancer pathogenesis. However, DKK1 appears to increase tumour growth and metastasis in preclinical models and its elevated expression correlates with a poor prognosis in a range of cancers, indicating that DKK1 has more complex cellular and biological functions than originally appreciated. Here, we review current evidence for the cancer-promoting activity of DKK1 and recent insights into the effects of DKK1 on signalling pathways in both cancer and immune cells. We discuss the rationale and promise of targeting DKK1 for oncology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available